Groesbeck Investment Management Corp NJ Sells 260 Shares of ICON Public Limited (NASDAQ:ICLR)

Groesbeck Investment Management Corp NJ cut its holdings in ICON Public Limited (NASDAQ:ICLR) by 12.0% during the 4th quarter, HoldingsChannel reports. The fund owned 1,911 shares of the medical research company’s stock after selling 260 shares during the quarter. Groesbeck Investment Management Corp NJ’s holdings in ICON Public were worth $401,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of ICLR. Park Place Capital Corp grew its stake in shares of ICON Public by 281.4% in the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 166 shares in the last quarter. GAMMA Investing LLC lifted its position in ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after purchasing an additional 169 shares during the period. Whittier Trust Co. of Nevada Inc. lifted its position in ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after purchasing an additional 96 shares during the period. First Horizon Advisors Inc. lifted its position in ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after purchasing an additional 151 shares during the period. Finally, Avior Wealth Management LLC lifted its position in ICON Public by 76.0% during the fourth quarter. Avior Wealth Management LLC now owns 894 shares of the medical research company’s stock worth $187,000 after purchasing an additional 386 shares during the period. 95.61% of the stock is currently owned by institutional investors and hedge funds.

ICON Public Stock Down 1.1 %

Shares of NASDAQ:ICLR opened at $193.27 on Wednesday. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. The business has a fifty day simple moving average of $208.53 and a 200 day simple moving average of $256.54. ICON Public Limited has a 12-month low of $183.38 and a 12-month high of $347.72. The firm has a market cap of $15.94 billion, a P/E ratio of 21.55, a P/E/G ratio of 1.79 and a beta of 1.19.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ICLR. Redburn Atlantic began coverage on shares of ICON Public in a research report on Monday, October 14th. They set a “neutral” rating and a $311.00 price objective for the company. JPMorgan Chase & Co. cut their price objective on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a research report on Monday. Robert W. Baird cut their price objective on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research report on Wednesday, November 20th. William Blair reissued an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Finally, Baird R W downgraded ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Four analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $285.75.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.